Hepatocellular Carcinoma‐on‐a‐Chip Based on Microfluidic Well Array for Personalized Drug Evaluation
Advanced Healthcare Materials · 2026-07 · 15 (26)
DOI: 10.1002/adhm.71327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 03.06.2026. Verfasst von Sunhao Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Institute of Translational Medicine, College of Life Science, Nanjing Drum Tower Hospital, Nanjing Normal …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Lab-On-A-Chip Devices, Antineoplastic Agents. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Henan Province Science and Technology R&D Program.
Abstract (Originalsprache)
The high interpatient variability in hepatocellular carcinoma (HCC) poses a critical challenge to drug therapy, underscoring the need for personalized platforms that can assess therapeutic efficacy while capturing tumor heterogeneity. Here, we present a stereo microfluidic well array‐based hepatocellular carcinoma‐on‐a‐chip for one‐stop individualized drug evaluation. We design the device with two modules for tumor spheroid formation and drug concentration gradient generation in a single platform. Using projection micro‐stereolithography, the chip template is fabricated in a one‐step process and subsequently molded in polydimethylsiloxane (PDMS). Controlled microfluidic flow in the chip enables precise cell loading into microwells, producing uniform‐sized and high‐viability HCC spheroids (∼2200 per chip) under dynamic culture conditions. Based on these features, this tumor‐on‐a‐chip further supports high‐throughput drug screening across tunable and multiple concentration gradients, validated with patient‐derived HCC samples. Thus, this platform is capable of high‐throughput generation of three‐dimensional spheroids and multi‐dose drug gradient exposure; it has already completed proof‐of‐concept studies for a drug screening platform based on microfluidic spheroids, laying the groundwork for subsequent translational research incorporating clinical data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Institute of Translational Medicine, College of Life Science, Nanjing Drum Tower Hospital, Nanjing Normal University, Nanjing, China.
- School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
ORCID-Profile: Sunhao Jiang, Rui Liu, Yuanjin Zhao
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Henan Province Science and Technology R&D Program
- Key Research & Developement Program of Jiangsu Province
Zitieren
APA
Jiang, S., Wu, Z., Liu, R., & Zhao, Y. (2026). Hepatocellular Carcinoma‐on‐a‐Chip Based on Microfluidic Well Array for Personalized Drug Evaluation. Advanced Healthcare Materials, 15(26). https://doi.org/10.1002/adhm.71327
Vancouver
Jiang S, Wu Z, Liu R, Zhao Y. Hepatocellular Carcinoma‐on‐a‐Chip Based on Microfluidic Well Array for Personalized Drug Evaluation. Advanced Healthcare Materials. 2026;15(26). doi:10.1002/adhm.71327
BibTeX
@article{Jiang2026,
author = {Jiang, Sunhao and Wu, Zhuhao and Liu, Rui and Zhao, Yuanjin},
title = {Hepatocellular Carcinoma‐on‐a‐Chip Based on Microfluidic Well Array for Personalized Drug Evaluation},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {26},
doi = {10.1002/adhm.71327}
}
EUVIMED